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AbsTrACT
Objective Despite its predictive value for mortality in 
various diseases, the relevance of growth differentiation 
factor-15 (gDF-15) as prognostic biomarker in 
pulmonary hypertension (Ph) remains unclear. This 
study investigated the association between gDF-15 and 
outcomes in adults with Ph.
Methods This is a single-centre prospective 
observational cohort study. all adults with Ph were 
included at the day of their diagnostic right heart 
catheterisation between 2012 and 2016. Ph due to left 
heart disease was excluded. Venous blood sampling was 
performed and included gDF-15 and n-terminal pro-
B-type natriuretic peptide (nT-proBnP) measurements. 
Kaplan-Meier curves and cox regression analysis were 
used to investigate the association between gDF-15 and 
a composite endpoint of death or lung transplantation. 
We adjusted for age and nT-proBnP in multivariable 
analysis. reference values were established by gDF-15 
measurements in healthy controls.
results gDF-15 was measured in 103 patients 
(median age 59.2 years, 65% women, 51% pulmonary 
arterial hypertension). gDF-15 was elevated in 76 
patients (74%). after a median follow-up of 3.4 (iQr 
2.3–4.6) years, 32 patients (31.1%) reached the primary 
endpoint. event-free survival 2 years after diagnosis 
was 100% in patients with normal gDF-15 versus 
72.4% in patients with elevated gDF-15 (p=0.007). a 
significant association was found between gDF-15 and 
the primary endpoint (hr per twofold higher value 1.77, 
95% ci 1.39 to 2.27, p<0.001), also after adjustment 
for age and nT-proBnP (hr 1.41, 95% ci 1.02 to 1.94, 
p=0.038).
Conclusions high gDF-15 levels are associated with 
an increased risk of death or transplant in adults with 
Ph, independent of age and nT-proBnP. as non-specific 
biomarker, gDF-15 could particularly be useful to detect 
low-risk patients.
InTrOduCTIOn
Growth differentiation factor-15 (GDF-15) is a 
member of the transforming growth factor-B cyto-
kine superfamily and is known for its role in cell 
growth and differentiation.1 Animal models have 
shown that GDF-15 is induced in response to cardiac 
pressure overload, ischaemia, oxidative stress and 
reperfusion injury.2 3 However, GDF-15 is non-tissue 
specific; secretion of GDF-15 is produced by a 
wide variety of cells4 and is seen in high concen-
trations in various diseases.5 It may therefore not 
be surprising that GDF-15 has been identified as 
predictor for all-cause mortality in a wide spectrum 
of diseases: cardiovascular diseases,6 7 various types 
of cancers8 9 and pulmonary diseases.10 11 To that 
end, the use of GDF-15 in risk stratification has been 
doubted because of its lack of disease specificity.12 
Paradoxically, non-tissue specific biomarkers could 
offer a solution in some diseases in which heteroge-
neity and concomitant disease have a considerable 
influence on the prognosis.
Pulmonary hypertension (PH) is a disease in which 
heterogeneity introduces major challenges in risk 
stratification. PH is defined by an increased pulmo-
nary artery pressure of ≥25 mm Hg13 which even-
tually leads to right ventricular failure and mortality. 
However, underlying aetiology of increased pulmo-
nary pressures includes a wide spectrum of diseases. 
The prognosis of PH strongly depends on the aeti-
ology.14 A recent study including PH of all aetiolo-
gies showed that only in 23.8% of the patients right 
ventricular failure was the main cause of death and 
other causes such as respiratory failure, malignancy, 
sepsis and infection were not uncommon.15 In this 
perspective, GDF-15 could be an ideal prognostic 
biomarker for mortality risk stratification in PH, as it 
may reflect not only cardiac failure but also incorpo-
rate more disease processes.
Therefore, this study aimed to investigate levels of 
GDF-15 in adults with PH of different aetiologies at 
the time of diagnosis and to determine its association 
with prognosis. A cohort of healthy volunteers was 
used to establish reference values for GDF-15.
MeThOds
Patient and public involvement
Patients or the public were not involved in the 
design, or conduct, or reporting, or dissemination 
of our research.
study design
This prospective observational cohort study aimed to 
include all consecutive adults diagnosed with PH in 
our tertiary centre between May 2012 and October 
2016. The diagnostic work-up of PH consisted of an 
inpatient visit during which the following tests were 
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Figure 1 Kernel density plot showing the distribution of growth 
differentiation factor-15 (GDF-15) in healthy controls and in adults 
with pulmonary hypertension. The 97.5th percentile of the GDF-15 
distribution in the healthy controls is indicated by the black-dotted line. 
The x-axis is shown on the 2-log scale.
and pulmonary physician, 6 min walking test, 12-lead ECG, 
transthoracic echocardiography, venous blood sampling, cardiac 
CT and right heart catheterisation. Baseline was defined as the 
day of the diagnostic right heart catheterisation. Diagnosis of 
PH was defined as a mean pulmonary artery pressure ≥25 mm 
Hg. Exclusion criteria were unconfirmed diagnosis of PH due 
to an incomplete diagnostic work-up, not PH treatment-naive, 
<18 years, not capable of understanding or signing informed 
consent and PH due to left heart disease. The study protocol was 
approved by the local medical ethics committee and is conform 
to the principles outlined in the Declaration of Helsinki.
Classification of PH was done in accordance with the WHO 
classification: pulmonary arterial hypertension (PAH), PH due 
to lung disease, chronic thromboembolic pulmonary hyperten-
sion (CTEPH) and PH with unclear/multifactorial mechanisms 
(WHO 5). PAH was further subdivided according to the clas-
sification.13 16 Self-declared healthy volunteers were recruited 
between January 2014 and December 2014 to serve as control 
cohort. All volunteers underwent physical examination, ECG, 
echocardiography and venous blood sampling on the same day. 
More detailed information has been previously published.17
data collection
Transthoracic echocardiography was performed using a commer-
cially available ultrasound system (ie, 33, Philips Medical 
Systems, Best, the Netherlands). The echocardiographic imaging 
analysis was performed in accordance with echocardiographic 
guidelines on cardiac chamber quantification.18 We used a Swan-
Ganz catheter to obtain haemodynamic measurements during 
the right heart catheterisation. Fick’s principle or thermodilu-
tion was used to measure cardiac output. On indication, a fluid 
challenge was performed to distinguish PH due to left heart 
disease from precapillary PH. Data were collected and stored 
in an online electronic case report form (PAHTool, version 
4.3.5947.29411; Inovoltus, Santa Maria da Feira, Portugal). 
More details have been described previously.19
biomarker assessment
Venous blood sampling was performed during the diagnostic 
right heart catheterisation and was for study purposes only. 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 
directly measured from fresh blood samples with the use of an 
electrochemiluminescence assay (Roche Diagnostics) in the clin-
ical chemistry laboratory. The rest of the serum samples were 
aliquoted and stored in our biobank by −80°C. GDF-15 was 
determined in thawed serum samples by batch analysis with elec-
trochemiluminescence immunoassay using the Cobas 6000 anal-
yser (Roche Diagnostics, Basel, Switzerland). Limit of detection 
was 400 pg/mL. GDF-15 was measured once in all patients with 
PH. In healthy controls, GDF-15 was measured twice to assess 
reproducibility and to establish reference values.
definition of endpoints
Endpoints were defined prior to data collection. The primary 
endpoint was defined as all-cause mortality or lung transplan-
tation. The secondary endpoint was a composite endpoint 
including the elements of the primary endpoint and heart failure. 
Heart failure was defined as any hospitalisation due to heart 
failure with requirement for uptitration or initiation of diuretics.
Protocolled half-yearly visits to the outpatient clinic were 
scheduled to guarantee data on endpoints. Patients were treated 
in accordance with the European Society of Cardiology (ESC) 
guidelines.13 PH medication was prescribed when indicated and 
patients with CTEPH eligible for pulmonary endarterectomy or 
balloon pulmonary angioplasty were referred to a specialised 
centre.
Patient records and the municipal personal records database 
were used to adjudicate the endpoints until 1 January 2019 
without the knowledge of any biomarker level.
statistical analysis
Continuous variables are presented as mean±SD or median 
(IQR). Differences in baseline characteristics between patients 
with a normal and elevated GDF-15 were investigated with 
the Student’s t-test or Mann-Whitney test (n<30) for contin-
uous variables. Differences in categorical variables were investi-
gated with the χ2 test or Fisher exact test. Correlations between 
GDF-15 and clinical characteristics were assessed with Pearson 
or Spearman correlation.
Reproducibility of GDF-15 assay was visualised by a Bland-Al-
tman plot and the coefficient of variation and intraclass correla-
tion coefficient were calculated. The 97.5th percentile based on 
2-log transformed GDF-15 distribution in healthy controls was 
used to define an elevated GDF-15 level. GDF-15 distributions 
were visualised using a Kernel density plot.
GDF-15 and NT-proBNP levels were 2-log transformed 
because of skewed distributions. Missing data were taken care 
of using multiple imputation with five imputations considering 
all meaningful variables as predictor, including the endpoints. 
Endpoints were not imputed. Pooled estimates were obtained 
based on Rubin’s rule.20 Survival curves were derived using the 
Kaplan-Meier estimator and compared with the log-rank test. 
Cox-proportional hazard regression was used to assess associ-
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Table 1 Baseline characteristics of all patients and subdivided to patients with a normal GDF-15 and elevated GDF-15 at baseline








Age, years 103 (100) 59 (47–69) 50 (29–63) 63 (53–70) 0.001
Sex, women 103 (100) 67 (65) 19 (70) 48 (63) 0.500
Heart rate, beats/minute 103 (100) 80±17 80±19 80±16 0.986
Systolic blood pressure, mm Hg 103 (100) 127±18 128±17 126±18 0.611
Oxygen saturation <90%, n (%) 103 (100) 3 (3) 1 (4) 2 (3) 1.00
Body mass index, kg/m² 103 (100) 28.2±6.5 26.7±6.0 28.8±6.7 0.153
  Overweight (25–30 kg/m2) 29 (28) 10 (37) 19 (25)
  Obesity (>30 kg/m2) 41 (40) 7 (26) 34 (45)
Diabetes mellitus 103 (100) 22 (21) 3 (11) 19 (25) 0.130
Systemic hypertension 103 (100) 25 (24) 3 (11) 22 (29) 0.063
NYHA class, n (%) 103 (100) 0.086
  Class I 1 (1) 1 (4) 0 (0)
  Class II 45 (44) 13 (48) 32 (42)
  Class III 47 (45) 13 (48) 34 (45)
  Class IV 10 (10) 0 (0) 10 (13)
eCG
Rhythm 100 (97) 0.753
Sinus 89 (89) 25 (92) 64 (88)
Atrial fibrillation 7 (7) 1 (4) 6 (8)
Other 4 (4) 1 (4) 3 (4)
QRS duration, ms 99 (96) 99 (90–106) 94 (88–106) 100 (91–106) 0.311
6 min walking test
Distance, m 90 (87) 339±139 398±131 317±137 0.015
echocardiography
RA area, cm² 79 (77) 27.4±8.9 23.3±6.8 28.8±9.2 0.016
RV basal dimension, mm 74 (72) 51.3±9.6 48.8±9.0 52.3±9.7 0.169
RV fractional area change, % 72 (70) 29.0±8.5 28.3±6.5 29.3±9.2 0.672
TAPSE, mm 71 (69) 19.4±5.0 18.2±5.0 19.7±5.0 0.263
LV function 0.435
  Normal 97 (94) 65 (67) 19 (79) 46 (63)
  Mildly impaired 28 (29) 5 (21) 23 (32)
  Moderately impaired 3 (3) 0 (0) 3 (4)
  Severely impaired 1 (1) 0 (0) 1 (1)
LV end diastolic dimension, mm 43.4 (37.8–48.0) 44.8 (39.4–47.8) 42.8 (37.5–48.2) 0.751
right heart catheterisation
mPAP, mm Hg 103 (100) 42.0 (35.0–51.0) 42 (32–55) 41 (35–51) 0.546
mRAP, mm Hg 103 (100) 10.0±5.4 7.6±3.8 10.8±5.6 0.008
PAWP, mm Hg 89 (86) 13.2±6.3 12.7±6.4 13.4±6.3 0.673
PVR, wood units 86 (83) 5.5 (3.3–9.2) 5.7 (3.3–8.5) 5.2 (3.2–9.5) 0.691
Cardiac output, L/min 98 (95) 5.0 (4.0–6.1) 5.0 (4.1–5.7) 4.9 (4.0–6.4) 0.754
Cardiac index, L/min/m2 98 (95) 2.6 (2.2–3.2) 2.7 (2.3–3.1) 2.6 (2.1–3.4) 0.562
CT
PA diameter, mm 98 (95) 34.4±5.4 34.8±6.7 34.2±4.9 0.618
PA/AO ratio 98 (95) 1.12±0.24 1.24±0.35 1.09±0.16 0.035
Laboratory
NT-proBNP, pmol/L 103 (100) 63 (21–218) 24 (7–77) 90 (26–82) 0.001
eGFR 103 (100) 72 (56–90) 78 (72–90) 67 (52–82) 0.002
Elevated GDF-15 was defined as: GDF-15 >920 pg/mL (age <50 years) or GDF-15 >1330 pg/mL (age >50 years).
AO, aorta; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; LV, left ventricular; mPAP, mean pulmonary artery pressure;mRAP, mean right 
atrial pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide;NYHA, New York Heart Association; PA, pulmonary artery; PAWP, pulmonary artery wedge pressure;PVR, 
pulmonary vascular resistance; RA, right atrial; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.
The proportional hazard assumption was assessed through 
Schoenfield residual plots and through proportional hazard 
tests. We adjusted all analyses for age because we considered 
this as an important confounder. Due to the limited number of 
events, we adjusted for only one additional clinical variable at a 
time in additional analyses. A subgroup analysis was performed 
restricted to patients with PAH, with adjustment for only one 
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Body mass index 0.02 0.859
Heart rate 0.15 0.128
Systolic blood pressure −0.21 0.032
Oxygen saturation <90% −0.09 0.380
NYHA class 0.28 0.004
Diabetes 0.31 0.001
Systemic hypertension 0.30 0.002
eCG
Loss of sinus rhythm 0.10 0.316
QRS duration 0.09 0.362
6 min walking test
Distance −0.44 <0.001
echocardiography
Right atrial area 0.16 0.174
RV basal dimension 0.08 0.487
RV fractional area change −0.05 0.651
TAPSE, mm −0.04 0.743
LV function 0.15 0.143





Pulmonary vascular resistance 0.18 0.091
Cardiac output −0.11 0.272
Cardiac index −0.18 0.083
CT
PA diameter −0.081 0.427




Significant correlations are in bold. 2-log transformed GDF-15 levels were used for 
the analysis.
AO, aorta; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation 
factor-15; LV, left ventricular; mPAP, mean pulmonary artery pressure; mRAP, mean 
right atrial pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, 
New York Heart Association; PA, pulmonary artery; PAWP, pulmonary artery wedge 
pressure; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.
Figure 2 Distribution of PH subdiagnoses according to a normal 
or elevated GDF-15 and according to the primary endpoint. Elevated 
GDF-15 was defined as: >920 pg/mL (age <50 years) or >1330 pg/
mL (age >50 years). Diagnosis groups are in accordance with the ESC 
guidelines of PH. PAH-other consisted of: pulmonary veno-occlusive 
disease (n=2), PAH-associated with portal hypertension (n=7), 
hereditary PAH (n=2), drug-induced and toxin-induced PAH (n=1). 
CTEPH, chronic thromboembolic pulmonary hypertension; GDF-15, 
growth differentiation factor-15; iPAH, idiopathic pulmonary arterial 
hypertension; PAH-CHD, pulmonary arterial hypertension due to 
congenital heart disease, PAH-CTD, pulmonary arterial hypertension due 
to connective tissue disease; PH, pulmonary hypertension; WHO5=WHO 
group 5.
To evaluate the potential predictive value of GDF-15 beyond age 
and NT-proBNP, we determined C-indices of models with and 
without GDF-15. The likelihood ratio test was used to compare 
models.
Statistical analyses were performed using IBM SPSS Statistics 
(version 24) and R version 5.5.3. A two-sided p-value <0.05 was 
considered statistically significant.
resuLTs
reproducibility of GdF-15 assay and reference values
GDF-15 was measured twice in 145 healthy controls. Repro-
ducibility of the assay was good, with coefficient of variation 
of 0.68%, limits of agreement of −15.49 to 23.60 pg/mL and 
intraclass correlation coefficient of 0.99 (0.99–1.00, p<0.001) 
(online supplementary file 1). Levels ranged from 400 pg/mL 
(lower limit of detection; n=15) to 1495 pg/mL. GDF-15 was 
not significantly different between men and women; however, 
there was a significant correlation with age (r=0.48, p<0.001) 
(online supplementary file 2). Consequently, age-specific refer-
ence values were established: >920 pg/mL for patients aged <50 
years and 1330 pg/mL for patients aged >50 years. Distribution 
of GDF-15 levels in healthy controls and patients with PH is 
shown in figure 1.
baseline characteristics
GDF-15 was measured in 103 out of 106 patients (97%) who 
were originally included in this study (online supplementary file 
2). In three cases, no serum sample was traceable to measure 
GDF-15. Median age was 59 (IQR 47–69) years, 67 were women 
(65%) and 52 had PAH (51%). Over half of the patients was in 
New York Heart Association (NYHA) functional class III (46%) 
or IV (10%). GDF-15 was above the limit of detection in all 
patients, with a median GDF-15 of 1974 (IQR 1096–4173) pg/
mL. An elevated GDF-15 was found in 76 patients (74%). 
Patients with normal GDF-15 were significantly younger, had 
a longer 6 min walking distance, a lower right atrial area and 
mean right atrial pressure, a better renal function and a lower 
NT-proBNP, than patients with elevated GDF-15 (table 1).
Higher GDF-15 significantly correlated with higher NYHA 
class, shorter 6 min walking distance and the presence of 
hypertension and diabetes mellitus. GDF-15 did not show 
any significant correlation with echocardiographic or invasive 
haemodynamic measures, except for the mean right atrial pres-
sure. GDF-15 did show a significant moderate correlation with 
NT-proBNP (r=0.51, p<0.001) and estimated glomerular filtra-
tion rate (eGFR) (r=−0.47, p<0.001) (table 2).
There was no statistical difference in GDF-15 distributions 
across PH subgroups (p=0.061) (online supplementary file 3). 
The distribution of different PH aetiologies across patients with 
normal versus elevated GDF-15 is presented in figure 2.
Follow-up
Follow-up data were 100% complete. Median follow-up was 3.4 
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Figure 3 Survival curve demonstrating the cumulative transplant-free 
survival in patients with pulmonary hypertension with a normal growth 
differentiation factor-15 (GDF-15) level and patients with an elevated 
GDF-15 level. An elevated GDF-15 was defined as: GDF-15 >920 pg/mL 
(age <50 years) or GDF-15 >1330 pg/mL (age >50 years).
Table 3 Association between GDF-15 and the primary and secondary endpoint
Primary endpoint (n=32) secondary endpoint (n=41)
hr* (95% CI) P value hr* (95% CI) P value
GDF-15 (univariable) 1.77 (1.39 to 2.27) <0.001 1.58 (1.27 to 1.96) <0.001
Adjusted for:
Age and sex 1.74 (1.34 to 2.26) <0.001 1.53 (1.21 to 1.93) <0.001
Age and NYHA class 3/4 1.60 (1.23 to 2.08) <0.001 1.40 (1.11 to 1.76) 0.005
Age and 6-MWD 1.57 (1.21 to 2.04) 0.001 1.31 (1.03 to 1.66) 0.025
Age and right atrial area 1.71 (1.32 to 2.20) <0.001 1.49 (1.19 to 1.87) 0.001
Age and cardiac index 1.77 (1.35 to 2.31) <0.001 1.53 (1.21 to 1.93) <0.001
Age and mRAP 1.78 (1.37 to 2.32) <0.001 1.46 (1.15 to 1.86) 0.002
Age and eGFR 1.72 (1.28 to 2.30) <0.001 1.48 (1.14 to 1.92) 0.003
Age and NT-proBNP 1.41 (1.02 to 1.94) 0.038 1.21 (0.91 to 1.62) 0.192
*HR per twofold higher value of GDF-15.
eGFR, estimated glomerular filtration rate;GDF-15, growth differentiation factor-15; mRAP, mean right atrial pressure; 6-MWD, 6 min walking distance; NT-proBNP, N-terminal pro 
B-type natriuretic peptide; NYHA, New York Heart Association.
patients (31.1%), and the secondary endpoint was reached in 41 
patients (39.8%). Figure 1 shows the distribution of PH aetiol-
ogies according to primary endpoint achievement. Considering 
all endpoints separately, 30 patients died, 4 patients underwent 
lung transplantation and 26 patients were hospitalised for heart 
failure. Causes of death were end-stage heart failure (n=9), 
sudden death presumed cardiac (n=4), multiorgan failure 
(n=3), and other diverse causes (n=13) described in detail 
in online supplementary file 5. In one patient, cause of death 
was unknown. PAH-specific medication was initiated during 
follow-up in 90% of the patients with PAH (n=47) and in 71% 
of the patients with CTEPH (n=15). Five patients (24%) with 
CTEPH underwent balloon pulmonary angioplasty and three 
patients (14%) underwent surgical pulmonary endarterectomy.
GdF-15 as prognostic biomarker
Patients with normal GDF-15 had a significant higher trans-
plant-free survival than patients with elevated GDF-15 
(p=0.007). This difference was specifically pronounced within 
the first 2 years of follow-up; patients with normal GDF-15 were 
all alive and free of transplantation up to 2 years after diagnosis, 
compared with 72.4% of the patients with elevated GDF-15. 
Comparable results were found regarding the secondary 
endpoint (figure 3).
Analysed continuously, GDF-15 was significantly associated 
with the primary endpoint, also after adjustment for several clin-
ical characteristics. After adjustment for age and NT-proBNP, 
GDF-15 was still significantly associated with the primary 
endpoint. Addition of GDF-15 to a model with NT-proBNP and 
age, significantly increased the C-index from 0.73 (95% CI 0.65 
to 0.81) to 0.76 (95% CI 0.69 to 0.83) (p=0.042).
GDF-15 was significantly associated with the secondary 
endpoint, although less strong compared with the primary 
endpoint. This association remained present after adjustment 
for clinical characteristics, but not after adjustment for age and 
NT-proBNP (table 3).
Subgroup analysis restricted to PAH showed an independent 
prognostic value of GDF-15 for the primary endpoint when 
adjusted for clinical variables, including NT-proBNP. Notably, 
adjustment for eGFR led to a non-significant result in this 
subgroup (online supplementary file 6).
dIsCussIOn
In 76% of the patients with PH, GDF-15 is elevated at the time of 
the diagnosis. Higher GDF-15 levels were associated with an older 
age, higher NYHA class, shorter 6 min walking distance, higher 
mean right atrial pressure and higher NT-proBNP; however, no 
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GDF-15 was significantly associated with mortality or lung 
transplantation independent of age and NT-proBNP levels, and 
yielded an incremental predictive value. Moreover, a normal 
GDF-15 ruled out the risk of death or transplantation in the first 
2 years after the diagnosis of PH.
Previous reports
Data on GDF-15 in adults with PH are currently limited and 
are restricted to some specific PAH diagnoses. Nickel et al 
measured GDF-15 in 76 treatment-naive adults with idio-
pathic PAH (iPAH), 55% of these patients had a GDF-15 level 
above 1200 ng/L. Higher GDF-15 levels were associated with 
an increased risk of death or transplantation, independent of 
NT-proBNP and other clinical variables.10 Rhodes et al later 
confirmed the predictive value of GDF-15 for mortality in 
139 patients with iPAH.21 Zelniker et al investigated GDF-15 
in 96 non-treatment naive patients with PAH. The majority of 
these patients had iPAH (68%) or PAH due to connective tissue 
disease (22%). They found that higher GDF-15 levels were asso-
ciated with the 4-year mortality risk. However, GDF-15 was not 
a better prognosticator than NT-proBNP, high-sensitive tropo-
nin-T and proatrial natriuretic peptide in their study.22
Cross-sectional studies have shown that GDF-15 is higher 
in patients with PAH due to systemic sclerosis compared with 
patients with systemic sclerosis free of PAH.23 Moreover, higher 
levels of GDF-15 were found in patients with CTEPH compared 
with patients with a history of acute pulmonary embolism 
without development of CTEPH.24
To the best of our knowledge, this is the first study investi-
gating GDF-15 in a group of mixed PH aetiologies. It showed 
that GDF-15 levels are considerably higher in adults with PH 
compared with a reference cohort and that a GDF-15 level within 
the reference range is associated with a low risk of mortality, 
transplantation or heart failure in adults with PH. GDF-15 could 
therefore be a promising biomarker. However, the price of the 
GDF-15-assay kit is still high and ideally biomarkers should be 
easily measured against a low price.
underlying mechanisms of GdF-15
There are several possible explanations for the high GDF-15 
levels in patients with PH and its strong association with mortality 
found in our study. First, since GDF-15 is involved in the regu-
lation of cell processes and PH is characterised by pulmonary 
vascular endothelial remodelling,25 GDF-15 could reflect the 
process of vascular remodelling in PH. This is supported by a 
study that found higher GDF-15 levels in the vascular endothe-
lial cells of PH.26 Second, GDF-15 may be induced by myocar-
dial cell stress caused by the increased right ventricular afterload 
as it has been shown that GDF-15 is induced in the myocar-
dium of mice after exposure to ischaemic injury.2 Moreover, it 
has been suggested that GDF-15 is part of a cardioprotective 
pathway.3 Third, GDF-15 may have been secreted due to any 
concomitant disease in these patients such as systemic sclerosis 
or chronic obstructive pulmonary disease. Finally, it has been 
shown that GDF-15 levels are higher in patients with diabetes 
and other unfavourable cardiovascular risk factors.27 In our 
study, 21% of the patients had diabetes mellitus and 24% had 
systemic hypertension and both comorbidities correlated with 
higher GDF-15 levels.
Considering all of the above-mentioned reasons, it is most 
presumable that GDF-15 levels were influenced by more 
disease processes than solely cardiac involvement. This can be 
further supported by the fact that levels of GDF-15 did show 
an association with NYHA class and the 6 min walking distance, 
while associations with haemodynamic or echocardiographic 
measurements were mostly absent. Despite limited associa-
tions with cardiac pressure and function, GDF-15 did show a 
moderate positive correlation with NT-proBNP.
The prognosis of adults with PH is still very challenging, 
mainly due to heterogeneity and accompanied diseases in this 
population. Paradoxically, as we hypothesised, in this specific 
setting the low disease specificity of GDF-15 turns out advan-
tageous and could serve as prognostic biomarker to detect 
patients with low-risk PH. Restricting the survival analysis to 
only patients with PAH showed approximately the same prog-
nostic value. This strengthens the idea that GDF-15 could be a 
prognostic biomarker in patients with PH independent of the 
specific underlying aetiology. Furthermore, GDF-15 showed 
an independent association with the primary endpoint when 
adjusted for age and NT-proBNP, and provided an incremental 
predictive value.
Limitations
Blood sampling was performed during the diagnostic right 
heart catheterisation in treatment-naive patients with PH. In 
patients with PAH and CTEPH, treatment was initiated directly 
after confirmation of diagnosis. We were not able to adjust for 
treatment effect in the association between GDF-15 and the 
endpoints. This study therefore reflects the association between 
GDF-15 and adverse outcomes for patients with PH treated in 
accordance to the ESC guidelines.
Patients with PH due to left heart disease were not included in 
this study, and this should be kept in mind when extrapolating 
the results to other studies. Also our study consisted of a hetero-
geneous group of PH aetiologies and subgroup analysis could 
only be performed for PAH. It should be kept in mind that clin-
ical usefulness of GDF-15 might differ among PH aetiologies. 
Furthermore, this study focused only one a single prognosticator 
and due to the limited statistical power, the additive value of 
GDF-15 to existing risk scores could not be assessed. Conclu-
sion with regard to the use of this biomarker in the context of 
current risk models, specifically concerning patients with PAH, 
are therefore limited.
Clinical implications
GDF-15 showed a strong association with mortality in our study 
and specifically identified low-risk patients at the time of diag-
nosis of PH. Therefore, measuring GDF-15 may be considered in 
patients with newly diagnosed PH to identify, and subsequently 
reassure, low-risk patients. In these patients, the follow-up 
frequency could probably be lowered compared with high-risk 
patients. Since GDF-15 is not tissue-specific and concentrations 
can rise or decline in response to any disease process, GDF-15 
seems not the most optimal biomarker to specifically pursue 
biomarker-guided therapy. Nevertheless, more data are needed 
to validate these findings before finding its way to daily clinical 
practice and larger studies with more power are needed to inves-
tigate GDF-15 in the light of current existing risk prediction 
models for PAH.
COnCLusIOns
In adults with PH, a normal GDF-15 level at the time of diag-
nosis identifies patients with a very low 2-year risk of mortality 
or transplantation. GDF-15 could therefore be a promising 
biomarker to identify low-risk patients with normal GDF-15 
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in future biomarker-guided therapy is uncertain and may be 
limited; however, GDF-15 could potentially serve as predictor 
for mortality in patients with PH of various aetiologies. Future 
studies, preferably including a larger cohort of patients with 
PH, are recommended to further investigate this promising 
biomarker.
Key messages
What is already known on this subject?
 ► Growth differentiation factor-15 (GDF-15) is a non-tissue 
specific biomarker and has been identified as strong 
predictor for mortality in various disease. Risk stratification in 
pulmonary hypertension remains challenging because of the 
considerable heterogeneity in this disease population.
What might this study add?
 ► GDF-15 is significantly associated with the transplant-free 
survival in adults with pulmonary hypertension patients, 
independent of N-terminal pro-B-type natriuretic peptide 
levels. A normal GDF-15 level at the time of diagnosis 
identifies patients with a very low 2-year mortality risk.
how might this impact on clinical practice?
 ► In adults with pulmonary hypertension, a GDF-15 
measurement at the time of diagnosis should be considered 
to identify low-risk patients whom can be reassured.
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